Biotech Startups

UniteLabs provides a lab automation platform that lets biotech and pharma teams define and run laboratory workflows as Python code, integrating 175+ devices through a single cloud API. Its "Lab As Code" approach offers version control, bidirectional device connectivity, and integration with LIMS/ELN tools such as Benchling for R&D labs.

3 investors

Cogent Biosciences is a biotechnology company developing small molecule precision therapies for genetically driven diseases where the cause is linked to a specific genetic mutation. It runs a discovery organization in Boulder, Colorado, aiming to create treatments for patients with unmet medical needs.

3 investors

UroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology. The company commercializes approved therapies for bladder and upper tract cancers, with additional candidates in development.

3 investors

Terrestrial develops the Tacterra microarray patch platform, a dissolvable skin-patch technology for delivering therapies including GLP-1 without injection. The platform targets patients seeking more convenient, pain-free administration of next-generation therapeutics.

3 investors

Vandria is a pharmaceutical development company focused on translating scientific innovation into first-in-class therapeutics. The company's management team specializes in mitochondrial function and neurological disease treatment.

3 investors

Vasa Therapeutics is a biopharmaceutical company focused on discovering and developing therapeutics that target the pathophysiology of cardiovascular aging. It operates from locations in California and Poland.

3 investors

VaxcellBio develops anti-cancer immunotherapies, including NK cell therapies, CAR cell therapies, targeted anti-cancer agents, and antibody treatments for cancers such as liver, small-cell lung, pancreatic, solid, and blood cancers. It also develops immuno-oncology products for companion animals, including treatments for mammary tumors and lymphoma.

3 investors

VELOZBIO manufactures food ingredients derived from germinated grains and legumes, using controlled germination to raise the nutritional value and technical functionality of its ingredients. Its products are aimed at formulators of high-protein and fortified food products.

3 investors

Velsera provides integrated software and expert services that turn complex biomedical and genomic data into usable insights for precision medicine, drug discovery, diagnostics development, and genetic testing. It serves organizations in the life sciences and healthcare sectors working on discovery, diagnostics, and regulatory navigation.

3 investors

Venus develops non-invasive, energy-based medical aesthetic devices for body, face, skin, and hair treatments, integrating robotics, AI, and IoT technologies. It serves medical spas, dermatologists, plastic surgeons, and hair transplant physicians across more than 60 countries.

3 investors

Veranex provides multi-disciplinary services to medical device and healthcare companies, supporting them from concept through commercialization of medical innovations. It positions itself as a partner to healthcare organizations across the medical product development process.

3 investors

Vera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant. The company was founded by a physician and operates as a clinical-stage biotech with a patient-centered approach to drug development.

3 investors

Verdiva Bio is a biotechnology company focused on drug development. Its leadership brings experience in in-licensing, commercialization, and business development across the international biotech industry.

3 investors

Vesalius Therapeutics develops a computational platform that identifies distinct disease subtypes within common diseases like heart failure, diabetes, and Alzheimer's by analyzing patient data and gene circuits, then uses proprietary cell-based models to discover targeted drug candidates. The company serves patients with prevalent chronic diseases using artificial intelligence, genomics, and patient-derived experimental models.

3 investors

ViaNautis develops targeted polyNaut nanovesicle (tPNV) delivery technology to advance cell and gene therapies and genetic medicines. A UCL spin-out originally established as SomaServe in 2018, the company operates from facilities in Cambridge, UK.

3 investors

ViAqua Therapeutics develops RNA-based solutions to treat diseases in aquaculture, specifically targeting viral pathogens like White Spot Shrimp Virus in shrimp through oral feed application. The company serves aquaculture producers and works with animal nutrition and health sectors in Israel.

3 investors

Vireo Ag offers the Whole Plant Delivery platform, a greenhouse-based plant genome engineering method that edits crops directly in soil without tissue culture, delivering stable seed in a single plant generation. The company licenses its patented tools and collaborates with crop-development companies across food, feed, fuel, and fiber to shorten breeding timelines.

3 investors

Viridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.

3 investors

Vironexis is a clinical-stage biotechnology company developing gene therapies that deliver vectorized T-cell engagers in a single IV dose through its in-vivo protein engineering approach. It is building a pipeline of more than 10 product candidates aimed at providing durable, T-cell-mediated cancer treatments.

3 investors

Vistim is a company leveraging neuroscience and artificial intelligence to develop solutions in the healthcare and medical technology space, drawing on expertise from neurology, brain-computer interfaces, EEG manufacturing, and pharmaceutical development.

3 investors

VisusNano develops ophthalmic drug delivery products, focusing on treatments for ocular and eye diseases. The company combines expertise in drug delivery, ophthalmic surgery, and clinical trials to create products for eye-care patients.

3 investors

Vitarka Therapeutics develops ENDOPORE, a drug delivery technology designed to transport therapeutic molecules into cells to treat diseases including cancer. The company operates in the biotechnology sector, focusing on solving a key challenge in drug development by enabling treatment targets that previously could not be reached.

3 investors

Vor Biopharma is a biopharmaceutical company. The available page content only covers its recruiting agency policy and does not describe its products or scientific focus.

3 investors

Walden Biosciences is a clinical-stage biotech company developing disease-modifying therapies that selectively target the kidney to treat the underlying drivers of kidney disease. Its pipeline aims to change the treatment landscape for patients with degenerative kidney diseases.

3 investors